Latest News
DIA and MHRA plan global regulatory science summit in London
10 July 2026 - The Drug Information Association (DIA), a US-based advisory organisation, and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) announced on Thursday the DIA-MHRA Global Summit: Global Collaboration for Safer and...
MetaVia completes DA-1726 dose titration in Phase 1 Part 3 study for obesity treatment
10 July 2026 - Clinical-stage biotechnology company MetaVia Inc (Nasdaq:MTVA) announced on Thursday that all enrolled active patients in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity have successfully completed ...
BiBBInstruments signs first European distribution deal for EndoDrill GI with Palex Spain
10 July 2026 - Swedish cancer diagnostics company BiBBInstruments AB (Spotlight Stock Market: BIBB) said on Thursday it has signed its first European commercial distribution agreement for its powered endoscopic biopsy system EndoDrill GI with Europea...
Teva and Polpharma Biologics enter global licensing agreement for biosimilar candidate to Ocrevus
9 July 2026 - Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA), announced on Thursday that it has entered into a global licensing agreement with biopharmaceutical company Polpharma Bio...
Ipsen reports positive Phase III results for Dysport in episodic and chronic migraine
9 July 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) on Thursday reported positive topline Phase III results from its BEOND migraine programme, with Dysport (abobotulinumtoxinA) meeting the primary endpoint in both ep...